首页|基于BiRNN模型的DPP-4和SGLT-2双靶点抑制剂设计

基于BiRNN模型的DPP-4和SGLT-2双靶点抑制剂设计

扫码查看
目的 设计DPP-4和SGLT-2 双靶点抑制剂。方法 根据现有的DPP-4和SGLT-2 活性化合物训练BiRNN模型,使其生成具有潜在活性的双靶点新分子,并使用已经报道的活性化合物构建HipHop药效团模型,通过药效团模型对新分子进行初筛,然后使用分子对接、分子动力学模拟以及结合自由能计算等方法对初筛小分子进行进一步筛选最终得到候选化合物。结果 BiRNN模型生成 7 494 个新分子,经过虚拟筛选发现化合物NM186、NM21、NM249、NM107 是相对理想的DPP-4 和SGLT-2 双靶点抑制剂。结论 NM186、NM21、NM249、NM107 可能是一种具有新型结构的DPP-4/SGLT-2 双靶点抑制剂,这一研究丰富了DPP-4和SGLT-2 双靶点抑制剂的多样性,为其开发提供新的设计思路。
Design of dual-target inhibitors of DPP-4 and SGLT-2 based on BiRNN model
Objective To design a dual-target inhibitor of DPP-4 and SGLT-2.Methods The BiRNN model was trained according to the existing DPP-4 and SGLT-2 active compounds to generate new dual-target molecules with potential activity,and the HipHop pharmacophore model was constructed using the reported active compounds,and the new molecules were pre-screened through the pharmacophore model,and then the small molecules were further screened by molecular docking,molecular dynamics simulation and combined free energy calculation,and the candidate compounds were finally obtained.Results A total of 7 494 new molecules were generated by the BiRNN model,and the compounds NM186,NM21,NM249,and NM107 were found to be relatively ideal dual-target inhibitors of DPP-4 and SGLT-2.Conclusion NM186,NM21,NM249 and NM107 may be dual-target inhibitors of DPP-4/SGLT-2 with novel structures,which enriches the diversity of DPP-4 and SGLT-2 dual-target inhibitors and provides new design ideas for their development.

diabetesSGLT-2/DPP-4 inhibitorsmolecular dockingpharmacophore modelmolecular dynamics simulations

孙定康、张鑫磊、郭凯蕾、李琦、梁佳龙、马丽莎、林佳艳、何金穗、刁春妍、王育伟、刘雪英

展开 >

陕西中医药大学 药学院,陕西 咸阳 712046

空军军医大学 药学系 药物化学与药物分析教研室,陕西 西安 710032

河南大学 生命科学学院,河南 开封 475004

中国人民解放军陆军第九四六医院 医疗保障中心,新疆 伊宁 835000

展开 >

糖尿病 SGLT-2/DPP-4抑制剂 分子对接 药效团模型 分子动力学模拟

陕西省秦创原"科学家+工程师"队伍建设

2023KXJ-080号

2024

现代药物与临床
天津药物研究院,中国药学会

现代药物与临床

CSTPCD
影响因子:1.179
ISSN:1674-5515
年,卷(期):2024.39(7)
  • 13